Literature DB >> 34297155

[Virtual prostatectomy using single dose radiotherapy].

Mohamed Shelan1, Elena Riggenbach2, Daniel M Aebersold2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34297155     DOI： 10.1007/s00066-021-01824-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report.

Authors:  Florien W Boele; Charles W Given; Barbara A Given; Heidi S Donovan; Richard Schulz; Jason M Weimer; Jan Drappatz; Frank S Lieberman; Paula R Sherwood
Journal:  Cancer       Date:  2016-10-27       Impact factor: 6.860

2.  Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Authors:  Thomas Zilli; Ciro Franzese; Marta Bottero; Niccolò Giaj-Levra; Robert Förster; Daniel Zwahlen; Nikolaos Koutsouvelis; Aurelie Bertaut; Julie Blanc; Giuseppe Roberto D'agostino; Filippo Alongi; Matthias Guckenberger; Marta Scorsetti; Raymond Miralbell
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

3.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

4.  Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study.

Authors:  Hannah Tharmalingam; Yatman Tsang; Peter Ostler; James Wylie; Amit Bahl; Anna Lydon; Imtiaz Ahmed; Christine Elwell; Ashok R Nikapota; Peter J Hoskin
Journal:  Radiother Oncol       Date:  2020-02-07       Impact factor: 6.280

5.  Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.

Authors:  Gerard Morton; Merrylee McGuffin; Hans T Chung; Chia-Lin Tseng; Joelle Helou; Ananth Ravi; Patrick Cheung; Ewa Szumacher; Stanley Liu; William Chu; Liying Zhang; Alexandre Mamedov; Andrew Loblaw
Journal:  Radiother Oncol       Date:  2020-03-05       Impact factor: 6.280

6.  Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial.

Authors:  Alfonso Gomez-Iturriaga; David Buchser; Esther Mayrata; Iñigo San Miguel; Alba Gonzalez; Fernan Suarez; Lorea Martinez-Indart; Pablo Minguez; Jose Espinosa; Fernando Perez; Jon Cacicedo; Francisco Casquero
Journal:  Radiother Oncol       Date:  2020-02-18       Impact factor: 6.280

7.  A biochemical definition of cure after brachytherapy for prostate cancer.

Authors:  Juanita M Crook; Chad Tang; Howard Thames; Pierre Blanchard; Jeremiah Sanders; Jay Ciezki; Mira Keyes; W James Morris; Gregory Merrick; Charles Catton; Hamid Raziee; Richard Stock; Frank Sullivan; Mitch Anscher; Jeremy Millar; Steven Frank
Journal:  Radiother Oncol       Date:  2020-04-27       Impact factor: 6.280

8.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

9.  Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Authors:  Douglas H Brand; Alison C Tree; Peter Ostler; Hans van der Voet; Andrew Loblaw; William Chu; Daniel Ford; Shaun Tolan; Suneil Jain; Alexander Martin; John Staffurth; Philip Camilleri; Kiran Kancherla; John Frew; Andrew Chan; Ian S Dayes; Daniel Henderson; Stephanie Brown; Clare Cruickshank; Stephanie Burnett; Aileen Duffton; Clare Griffin; Victoria Hinder; Kirsty Morrison; Olivia Naismith; Emma Hall; Nicholas van As
Journal:  Lancet Oncol       Date:  2019-09-17       Impact factor: 41.316
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.